Skip to content
Emend, Ivemend(fosaprepitant)
Emend, Ivemend (fosaprepitant) is a small molecule pharmaceutical. Fosaprepitant was first approved as Ivemend on 2008-01-11. It has been approved in Europe to treat neoplasms and vomiting. It is known to target substance-P receptor.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Emend (generic drugs available since 2016-06-09)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Fosaprepitant dimeglumine
Tradename
Company
Number
Date
Products
EMENDMerck Sharp & DohmeN-022023 RX2010-11-12
1 products, RLD, RS
FOSAPREPITANT DIMEGLUMINETevaN-210064 RX2019-09-05
1 products
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
fosaprepitantNew Drug Application2022-06-30
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration
Code
FOSAPREPITANT DIMEGLUMINE, EMEND, MERCK AND CO INC
2025-05-02D-186
Patent Expiration
No data
ATC Codes
No data
HCPCS
Code
Description
J1453
Injection, fosaprepitant, 1 mg
Clinical
Clinical Trials
62 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
VomitingD014839HP_0002013R11.159114331
NauseaD009325HP_0002018R11.01323211
Postoperative nausea and vomitingD020250EFO_00048881225
Breast neoplasmsD001943EFO_0003869C501113
Ovarian neoplasmsD010051EFO_0003893C5611
Uterine neoplasmsD014594EFO_0003859C5511
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369C801134
Major depressive disorderD003865EFO_0003761F2244
Nasopharyngeal neoplasmsD009303112
Multiple myelomaD009101C90.01112
Female genital neoplasmsD00583311
Digestive system surgical proceduresD01350511
Uterine cervical neoplasmsD00258311
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Non-small-cell lung carcinomaD00228911
Squamous cell carcinoma of head and neckD00007719511
Squamous cell carcinomaD00229411
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Traumatic brain injuriesD000070642S0611
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Gastrointestinal neoplasmsD005770C26.911
SarcomaD01250911
Colorectal neoplasmsD01517911
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameFOSAPREPITANT
INNfosaprepitant
Description
Fosaprepitant (Emend for Injection (US), Ivemend (EU)) is an antiemetic medication, administered intravenously. It is a prodrug of aprepitant.
Classification
Small molecule
Drug classphosphoro-derivatives; tachykinin (neurokinin) receptor antagonists: NK1 receptor antagonists
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
C[C@@H](O[C@H]1OCCN(Cc2nn(P(=O)(O)O)c(=O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1
Identifiers
PDB
CAS-ID172673-20-0
RxCUI1731071
ChEMBL IDCHEMBL1199324
ChEBI ID64321
PubChem CID219090
DrugBankDB06717
UNII ID6L8OF9XRDC (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
TACR1
TACR1
Organism
Homo sapiens
Gene name
TACR1
Gene synonyms
NK1R, TAC1R
NCBI Gene ID
Protein name
substance-P receptor
Protein synonyms
neurokinin receptor 1, NK-1 receptor, NK-1R, Tachykinin receptor 1, tachykinin receptor 1 (substance P receptor; neurokinin-1 receptor)
Uniprot ID
Mouse ortholog
Tacr1 (21336)
substance-P receptor (Q8BYR7)
Variants
Clinical Variant
No data
Financial
Emend - Merck Sharp & Dohme
$
£
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 520 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
3,594 adverse events reported
View more details